Niharika Tiwari Tiwari

Background: Solid tumors remain among the leading causes of global cancer mortality, with limited therapeutic options due to drug resistance, toxicity, and tumor heterogeneity. The convergence of nanomedicine and multi-omics technologies offers a novel strategy for precision oncology, enabling targeted drug delivery, biomarker-guided therapy, and improved monitoring of treatment response. Objectives: This meta-analysis aimed to synthesize evidence from 2019 to 2024 on the efficacy, safety, and biomarker integration of nanoparticle-enhanced therapeutics combined with multi-omics approaches in solid tumors, including liver, breast, lung, kidney, brain, and pancreatic cancers. Methods: A systematic search of PubMed, Scopus, and Web of Science was conducted following PRISMA guidelines. Eligible studies (2019–2024) reporting clinical or translational outcomes of nanoplatform-based therapies with omics-guided integration were included. Data were extracted on study design, sample size, tumor types, nanoparticle platforms, omics biomarkers, efficacy outcomes (response rates, progression-free survival [PFS], overall survival [OS]), and toxicity. Pooled analyses were performed using random-effects models. Results: A total of 62 studies comprising ~8,500 patients were included. Lipid-based (38%), polymeric (27%), inorganic (21%), and bioinspired/hybrid (14%) nanoplatforms were evaluated across multiple solid tumors. Pooled analysis demonstrated an improved overall response rate (ORR: 48% vs. 32%, pConclusions: Nanoparticle-enhanced therapeutics integrated with multi-omics approaches show significant promise in improving survival, reducing toxicity, and enabling biomarker-driven precision oncology in solid tumors. However, translational barriers—including tumor heterogeneity, blood–brain barrier penetration, and manufacturing scalability—must be overcome for widespread adoption. The future lies in AI-integrated, stimuli-responsive, bioinspired nanoplatforms guided by multi-omics data, supported by innovative trial designs to ensure clinical translation and equitable global access.

Background: Liver, breast, kidney, and brain cancers remain major contributors to global cancer morbidity and mortality. Conventional therapies are limited by systemic toxicity, drug resistance, and tumor heterogeneity. Smart nanoplatforms offer targeted delivery, controlled release, and theranostic capabilities to address these challenges. Objective: This systematic review evaluates the development and clinical translation of smart nanoplatforms between 2019 and 2024, focusing on their design, omics integration, therapy response, and clinical outcomes in liver, breast, kidney, and brain cancers. Methods: Studies published between 2019 and 2024 were systematically analyzed, encompassing preclinical research, clinical trials, and multi-omics-guided nanoparticle strategies. Nanoplatforms were categorized into lipid-based, polymeric, inorganic, and hybrid/bioinspired systems. The review highlights therapy response, biomarker monitoring, and adaptive approaches informed by omics data. Results: Lipid-based and polymeric nanoparticles demonstrated enhanced tumor targeting and reduced systemic toxicity. Inorganic and hybrid/bioinspired platforms enabled imaging-guided therapy and immune evasion. Integration of genomics, transcriptomics, proteomics, and metabolomics with AI-driven analytics facilitated personalized therapy and adaptive treatment strategies. Clinical trials reported improved patient tolerability, quality of life, and preliminary survival benefits, though translational barriers—including tumor heterogeneity, blood–brain barrier penetration, manufacturing, and regulatory hurdles—remain significant. Conclusions: Smart nanoplatforms represent a transformative approach to precision oncology. The combination of targeted delivery, multi-omics guidance, and AI-driven therapy optimization has the potential to enhance treatment efficacy and patient-specific outcomes. Future research should focus on scalable manufacturing, regulatory standardization, and integration of innovative trial designs to accelerate clinical adoption.